Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Pivotal bioVenture Partners Investment Advisor LLC
Form 13F · Q2 2026

Pivotal bioVenture Partners Investment Advisor LLC

CIK 1844645Filed 2026-08-1313F-HR View the filing on EDGAR ↗
$308M
Reported book value
13
Positions
12
Quarters on record
Top 50
Positions

Pivotal bioVenture Partners Investment Advisor LLC — holdings

Top 13 positions of 13, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1PCVX Vaxcyte Inc1.4M+3.9%$83M26.9%
2ARQT Arcutis Biotherapeutics Inc1.3M−6.7%$33M10.8%
3TRVI Trevi Therapeutics Inc1.7M+12.2%$33M10.6%
4AVALYN PHARMACEUTICALS INC Avalyn Pharmaceuticals Inc966,792—$32M10.3%
5EVMN Evommune Inc1.9M+0.0%$26M8.3%
6MPLT Maplight Therapeutics Inc611,446−0.0%$22M7.1%
7OCS Oculis Holding Ag1.5M−10.4%$21M6.8%
8BIOA Bioage Labs Inc653,374+0.0%$16M5.2%
9IMNM Immunome Inc732,512+0.0%$16M5.0%
10ZBIO Zenas Biopharma Inc490,766−17.1%$12M4.0%
11AVTX Avalo Therapeutics Inc434,033+46.7%$8M2.6%
12RLYB Rallybio Corp300,579+0.0%$5M1.6%
13RXRX Recursion Pharmaceuticals In595,518+0.0%$2M0.7%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.